A detailed history of Sei Investments CO transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Sei Investments CO holds 102,306 shares of DVAX stock, worth $1.13 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
102,306
Previous 117,974 13.28%
Holding current value
$1.13 Million
Previous $1.65 Million 23.04%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

SELL
$11.7 - $14.98 $183,315 - $234,706
-15,668 Reduced 13.28%
102,306 $1.27 Million
Q4 2023

Feb 14, 2024

SELL
$13.09 - $14.98 $98,934 - $113,218
-7,558 Reduced 6.02%
117,974 $1.65 Million
Q3 2023

Nov 14, 2023

BUY
$12.64 - $14.99 $989,876 - $1.17 Million
78,313 Added 165.85%
125,532 $1.85 Million
Q2 2023

Aug 11, 2023

BUY
$9.85 - $13.17 $143,238 - $191,518
14,542 Added 44.5%
47,219 $610,000
Q1 2023

May 12, 2023

BUY
$9.44 - $11.88 $28,178 - $35,461
2,985 Added 10.05%
32,677 $320,000
Q4 2022

Feb 10, 2023

SELL
$10.27 - $13.29 $102,864 - $133,112
-10,016 Reduced 25.22%
29,692 $315,000
Q3 2022

Nov 14, 2022

BUY
$9.93 - $17.44 $13,107 - $23,020
1,320 Added 3.44%
39,708 $414,000
Q2 2022

Aug 15, 2022

BUY
$7.45 - $12.83 $285,990 - $492,518
38,388 New
38,388 $490,000
Q4 2021

Feb 14, 2022

SELL
$13.17 - $20.94 $552,731 - $878,830
-41,969 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$9.16 - $19.83 $384,436 - $832,245
41,969 New
41,969 $806,000
Q4 2018

Feb 13, 2019

SELL
$8.14 - $13.28 $8,286 - $13,519
-1,018 Closed
0 $0
Q3 2018

Nov 08, 2018

SELL
$11.85 - $16.0 $24,351 - $32,880
-2,055 Reduced 66.87%
1,018 $9,000
Q2 2018

Aug 03, 2018

BUY
$15.15 - $20.75 $46,555 - $63,764
3,073 New
3,073 $47,000

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.4B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Sei Investments CO Portfolio

Follow Sei Investments CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

News

Stay updated on Sei Investments CO with notifications on news.